Speeding up Possible Anti-terrorism Patents

Researchers in a hurry to get their ideas off the drawing board and into the new defense race may take advantage of a special provision in U.S. patent law that allows rush treatment for anti-terrorism inventions. Scientists working in the areas of AIDS and cancer may already know about the rush rule; it has long allowed inventions in those areas to jump to the front of the line of applications awaiting review from the U.S. Patent and Trademark Office. After the crash of T.W.A. Flight 800 in 19

Written byPeg Brickley
| 3 min read

Register for free to listen to this article
Listen with Speechify
0:00
3:00
Share

After the crash of T.W.A. Flight 800 in 1996 once again raised the specter of organized attacks on domestic land, anti-hijacking devices, barricades, and other public safety-oriented inventions were added to the list of inventions entitled to ask for expedited handling.

Called an "application to make special," the speedy handling procedure costs an extra $130 in addition to the $740 patent application. But it may be worth it, suggested one patent attorney familiar with the provision. "Getting an application made special cuts about a year out of the time," says Scott J. Fields, partner at the Philadelphia law firm of Obermayer, Rebmann, Maxwell, & Hippel. "If you come up with an invention that will quickly seal off a door in the presence of gas or weapons, or a pill that will turn contaminated water blue, you may see things move even faster."

Universities active in the patent chase, however, say ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies